NewAmsterdam Pharma, an operator of a clinical-stage company, went public via a SPAC merger with Frazier Healthcare and Bain Capital-backed Frazier Lifesciences Acquisition in a $326m deal. “We believe that the transaction, if consummated, would provide us with the necessary capital to fund our business through 2026 and beyond multiple Phase 3 data readouts for obicetrapib, including our ongoing cardiovascular outcomes trial, and a potential global product launch. Cardiovascular disease remains a significant unmet need and is the number one cause of death in western countries, with high LDL levels being the chief culprit responsible for adverse outcomes and two-thirds of patients not reaching LDL goals despite the wide availability of statins. Adding a potential new convenient oral therapy that has been observed to confer an additional 51% of LDL-lowering on top of high dose statins could transform the treatment paradigm for this large patient population," Michael Davidson, NewAmsterdam Pharma CEO.